Gene Editing

Bill Gates Gets Excited About Future Of Tech That Has 'Revolutionized Health' Over Past Decade
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease

Gene Editing Recent News

Jennifer Doudna Spinout Mammoth Inks $700M CRISPR Deal With Vertex
Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate
Wave Life Sciences Shows Durable ADAR-Editing In Multiple Tissues In Animal Studies
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
Vertex Inks Potential $1.2B Gene-Editing Pact With Arbor Biotechnologies
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc.
Heart Disease Company Tenaya Therapeutics Files For $100M US IPO
WHO Issues Framework For Governance For Gene Editing Technologies
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body.
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments
Precision BioSciences Shares Move Higher As ARCUS Platform Shows Promising Gene Editing Approach For Transthyretin Amyloidosis
Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows
Cellectis, Cytovia Therapeutics Ink Gene-Edited Therapy Pact For Oncology Indications
Chinese 'Gene-Editing' Scientist Gets 3 Years In Prison
Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study
Baird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset